Reevaluation of sodium thiosulfate otoprotection using the consensus International Society of Paediatric Oncology Ototoxicity Scale: A report from the Children's Oncology Group study ACCL0431.

Abstract

In two randomized trials (Children's Oncology Group ACCL0431 and International Childhood Liver Tumour Strategy Group SIOPEL-6), sodium thiosulfate (STS) demonstrated efficacy in preventing cisplatin-induced hearing loss (CIHL). However, the measures used in those trials have been superseded by the consensus International Society of Paediatric Oncology (SIOP) Ototoxicity Scale. To provide benchmark data for STS efficacy when using this contemporary scale, we reanalyzed ACCL0431 hearing outcomes with the SIOP scale and using multiple timepoints. Compared to the control arm, STS significantly reduced CIHL when assessed by the SIOP scale across these different approaches. These results provide critical data to inform treatment discussions and support future potential trial designs comparing otoprotectants.

• Authors: Etan Orgel, Kristin R Knight, Doojduen Villaluna, Mark Krailo, Adam J Esbenshade, Lillian Sung, David R Freyer
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Pg. e30550 (Jul 07 2023) ISSN: 1545-5017 [Electronic] United States
• PMID: 37416942 (Publication Type: Journal Article)
• Copyright: © 2023 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.